Unknown

Dataset Information

0

Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability.


ABSTRACT: Peptidase neurolysin (Nln) is an enzyme that functions to cleave various neuropeptides. Upregulation of Nln after stroke has identified the enzyme as a critical endogenous cerebroprotective mechanism and validated target for the treatment of ischemic stroke. Overexpression of Nln in a mouse model of stroke results in dramatic improvement of stroke outcomes, while pharmacological inhibition aggravates them. Activation of Nln has therefore emerged as an intriguing target for drug discovery efforts for ischemic stroke. Herein, we report the discovery and hit-to-lead optimization of first-in-class Nln activators based on histidine-containing dipeptide hits identified from a virtual screen. Adopting a peptidomimetic approach provided lead compounds that retain the pharmacophoric histidine moiety and possess single-digit micromolar potency over 40-fold greater than the hit scaffolds. These compounds exhibit 5-fold increased brain penetration, significant selectivity over highly homologous peptidases, greater than 65-fold increase in mouse brain stability, and 'drug-like' fraction unbound in the brain.

SUBMITTER: Rahman MS 

PROVIDER: S-EPMC9295256 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability.

Rahman Md Shafikur MS   Kumari Shikha S   Esfahani Shiva Hadi SH   Nozohouri Saeideh S   Jayaraman Srinidhi S   Kinarivala Nihar N   Kocot Joanna J   Baez Andrew A   Farris Delaney D   Abbruscato Thomas J TJ   Karamyan Vardan T VT   Trippier Paul C PC  

Journal of medicinal chemistry 20210826 17


Peptidase neurolysin (Nln) is an enzyme that functions to cleave various neuropeptides. Upregulation of Nln after stroke has identified the enzyme as a critical endogenous cerebroprotective mechanism and validated target for the treatment of ischemic stroke. Overexpression of Nln in a mouse model of stroke results in dramatic improvement of stroke outcomes, while pharmacological inhibition aggravates them. Activation of Nln has therefore emerged as an intriguing target for drug discovery efforts  ...[more]

Similar Datasets

| S-EPMC8985228 | biostudies-literature
| S-EPMC9978853 | biostudies-literature
| S-EPMC6982609 | biostudies-literature
| S-EPMC8916014 | biostudies-literature
| S-EPMC8225578 | biostudies-literature
| S-EPMC9482816 | biostudies-literature
| S-EPMC10925177 | biostudies-literature
| S-EPMC5342060 | biostudies-literature
| S-EPMC3855312 | biostudies-literature
| S-EPMC6249066 | biostudies-literature